Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data
Abstract Objectives Fibrates are suitable for the treatment of patients with high triglyceride (TG) levels. Although pemafibrate (PEMA) has been reported to have beneficial and pleiotropic actions, clinical examinations of the efficacy of PEMA for Japanese patients with hypertriglyceridemia are stil...
Saved in:
| Main Authors: | Aki Okamoto, Hirohide Yokokawa, Tomoko Nagamine, Kento Goto, Hiroshi Fukuda, Teruhiko Hisaoka, Toshio Naito |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12902-025-01872-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01) -
Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study
by: Watanabe Y, et al.
Published: (2025-04-01) -
Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats
by: Masaya Okada, et al.
Published: (2025-05-01) -
Hypertriglyceridemia — current status of the problem. Part II: primary and secondary hypertriglyceridemias, treatment options
by: A. A. Semenkin, et al.
Published: (2025-03-01) -
Pemafibrate modulates peroxisome proliferator-activated receptor alpha and prevents alcohol-associated liver disease in rats
by: Takashi Saito, et al.
Published: (2025-04-01)